津巴布韦母乳喂养HIV女性长效抗逆转录病毒治疗的临床影响与成本效果模型
该微模拟模型评估了津巴布韦面临依从性挑战的产后HIV女性使用长效卡博特韦/利匹韦林(LA-CAB/RPV)相比口服TLD标准治疗的临床影响与成本效果。结果显示LA-ART可降低垂直传播(无病毒抑制组从7.49%降至6.58%,病毒抑制组从4.17%降至3.80%),每年避免约160例感染。无病毒抑制组LA-ART几乎不增加成本且改善儿童预期寿命;病毒抑制组ICER为2449美元/挽救生命年,当CAB/RPV年费用≤84美元时具成本效果。
要点
- LA-ART可降低面临依从性挑战的产后HIV女性垂直传播风险。
- 无病毒抑制组LA-ART几乎不增加成本且轻微改善儿童预期寿命。
- 病毒抑制组LA-ART在CAB/RPV年费用≤84美元时具成本效果。
核心结论
- 对于面临依从性挑战的母乳喂养HIV女性,LA-ART可减少婴儿感染。
- 无病毒抑制组LA-ART改善结局且几乎节省成本;病毒抑制组在CAB/RPV年费用≤84美元时具成本效果。
研究设计与样本
- 微模拟模型模拟津巴布韦 engaged in care 的产后HIV女性母婴配对,分为分娩时无病毒抑制(NVS)和病毒抑制(VS)两个队列,均孕期接受口服TLD。
- 比较产后标准治疗(继续TLD)与LA-ART(换用LA-CAB/RPV)两种策略。
主要发现
- LA-ART相比SOC降低垂直传播:NVS组从7.49%降至6.58%,VS组从4.17%降至3.80%,津巴布韦每年避免约160例感染。
- NVS组:SOC儿童预期寿命66.08年、成本764美元/儿童;LA-ART为66.40年、763美元/儿童。
- VS组:SOC儿童预期寿命67.40年、成本445美元/儿童;LA-ART为67.52年、555美元/儿童,ICER=2449美元/挽救生命年。
关键数值与推荐
- 6个月产后病毒抑制率:LA-ART组NVS=85%、VS=90%;SOC组NVS=63%、VS=78%。
- ART年费用:CAB/RPV=144美元,TLD=43.20美元。
- 垂直传播风险:0.06%-0.89%/月,范围随母亲RNA变化。
- 成本效果阈值:ICER≤800美元/挽救生命年(0.5倍津巴布韦GDP)。
- NVS组LA-ART在CAB/RPV年费用>228美元或6个月抑制率<74%时不再具成本效果;VS组在CAB/RPV年费用≤84美元时具成本效果。
临床怎么用
- 对于面临依从性挑战的产后HIV女性,可考虑LA-ART以降低垂直传播。
- NVS组LA-ART几乎不增加成本且改善儿童结局,可优先考虑。
- VS组使用LA-ART需确保CAB/RPV年费用≤84美元才具成本效果。
局限性
- LA-ART的疗效和药物成本存在不确定性,结论需在真实世界确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-acting antiretroviral therapy (LA-ART) may reduce adherence barriers for postpartum women with HIV (PPWH), reducing vertical transmission (VT) and improving pediatric life expectancy (pLE), but efficacy and drug costs are uncertain. METHODS: Using a microsimulation model, we simulated mother-infant dyads for two cohorts of PPWH engaged in care, receiving oral tenofovir/lamivudine/dolutegravir (TLD) in pregnancy, and facing adherence challenges in Zimbabwe: mothers without (NVS) and with (VS) viral suppression at delivery. We modeled two post-delivery strategies: standard of care (SOC: TLD continuation) or LA-ART (switching to LA-cabotegravir/rilpivirine [CAB/RPV]). Key inputs included: 6-month-postpartum viral suppression (LA-ART: NVS = 85%/VS = 90%; SOC: NVS = 63%/VS = 78%), ART costs/year (CAB/RPV=$144/TLD=$43.20), and VT risk (0.06%-0.89%/month, range by maternal RNA). Outcomes include VT, pLE, costs (maternal ART in breastfeeding plus pediatric HIV-related lifetime care), and incremental cost-effectiveness ratios (ICERs, $/year-of-life-saved [YLS]; cost-effective: ICER≤$800/YLS [0.5× Zimbabwe GDP]. RESULTS: LA-ART would reduce VT compared with SOC (NVS: from 7.49% to 6.58%/VS: from 4.17% to 3.80%), averting ∼160 infections/year in Zimbabwe. For NVS, LA-ART would improve pLE (SOC = 66.08y, LA-ART = 66.40y) at nearly equal cost (SOC = $764/child, LA-ART = $763/child); LA-ART would not be cost-effective if CAB/RPV cost >$228/year or 6-month suppression were <74%. For VS, LA-ART would lead to higher pLE and costs (67.52y, $555/child) than SOC (67.40y, $445/child), with ICER=$2449/YLS; LA-ART would become cost-effective if CAB/RPV cost ≤$84/year. CONCLUSIONS: LA-ART for breastfeeding women experiencing adherence challenges could reduce infant infections. If efficacies and costs are confirmed, LA-ART for NVS women would improve outcomes and be minimally cost-saving; for VS women, LA-ART would be cost-effective in Zimbabwe at costs ≤$84/year.
引用
- Tewari SE, Hoffman R, Lockman S, et al. Long-Acting Antiretroviral Therapy for Breastfeeding Women With HIV Experiencing Barriers to Adherence in Zimbabwe: Modeling Clinical Impact and Cost-effectiveness. J Infect Dis. 2026. PMID: 41324319. doi:10.1093/infdis/jiaf521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。